Have a feature idea you'd love to see implemented?
Let us know!
TRML Tourmaline Bio Inc
Price (delayed)
$28.26
Market cap
$724.62M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.26
Enterprise value
$654.58M
talaris therapeutics is a late-clinical stage biotechnology company based in boston, ma and louisville, ky. talaris is developing transformative cell therapies with the potential to eliminate the burden of chronic
Highlights
TRML's EPS has surged by 97% year-on-year and by 93% since the previous quarter
The company's debt has shrunk by 68% YoY and by 11% QoQ
TRML's equity has soared by 128% year-on-year but it is down by 4.5% since the previous quarter
The quick ratio has contracted by 25% from the previous quarter
Tourmaline Bio's net income has decreased by 4% QoQ
Key stats
What are the main financial stats of TRML
Market
Valuations
Earnings
Shares outstanding
25.64M
Market cap
$724.62M
Enterprise value
$654.58M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.14
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$35.69M
EBITDA
-$36.34M
Free cash flow
-$28.95M
Per share
Balance sheet
Liquidity
EPS
-$1.26
Free cash flow per share
-$1.13
Book value per share
$13.19
Revenue per share
$0
TBVPS
$13.4
Total assets
$344.79M
Total liabilities
$6.51M
Debt
$333,000
Equity
$338.28M
Working capital
$291.77M
Debt to equity
0
Current ratio
46.87
Quick ratio
45.55
Net debt/EBITDA
1.93
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-13.4%
Return on equity
-13.7%
Return on invested capital
-21.4%
Return on capital employed
-10.5%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
TRML stock price
How has the Tourmaline Bio stock price performed over time
Intraday
-0.14%
1 week
1.65%
1 month
22.87%
1 year
198.73%
YTD
7.94%
QTD
9.92%
Financial performance
How have Tourmaline Bio's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$44.32M
Net income
-$35.69M
Gross margin
N/A
Net margin
N/A
Tourmaline Bio's operating income has decreased by 14% from the previous quarter
Tourmaline Bio's net income has decreased by 4% QoQ
Growth
What is Tourmaline Bio's growth rate over time
Valuation
What is Tourmaline Bio stock price valuation
P/E
N/A
P/B
2.14
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
TRML's EPS has surged by 97% year-on-year and by 93% since the previous quarter
TRML's equity has soared by 128% year-on-year but it is down by 4.5% since the previous quarter
The price to book (P/B) is 43% higher than the last 4 quarters average of 1.5
Efficiency
How efficient is Tourmaline Bio business performance
The company's return on assets has shrunk by 163% YoY but it rose by 14% QoQ
Tourmaline Bio's ROE has plunged by 136% YoY but it has increased by 15% from the previous quarter
TRML's return on invested capital is up by 18% since the previous quarter
Dividends
What is TRML's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for TRML.
Financial health
How did Tourmaline Bio financials performed over time
The total assets has soared by 117% YoY but it has contracted by 4% from the previous quarter
TRML's total liabilities is down by 39% YoY but it is up by 29% from the previous quarter
The company's debt is 100% lower than its equity
TRML's equity has soared by 128% year-on-year but it is down by 4.5% since the previous quarter
The company's debt to equity has shrunk by 100% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.